Jeffrey R. Jackson

TL;DR: The codependence of chronic inflammation and angiogenesis is beginning to be understood, the potential benefits of targetingAngiogenesis in the treatment of chronicinflammation, and of targeting chronic inflammation to affect angiogenic research are begun.

TL;DR: These results support the proposed mechanism of action of ipilimumab, suggesting that cell-mediated immune responses play an important role in the antitumor activity of ipILimumab.

TL;DR: The advent of molecularly targeted drug discovery has facilitated the identification of a new generation of anti-mitotic therapies that target proteins with specific functions in mitosis, and these potential therapies serve as unique tools to dissect the molecular mechanisms of the mitotic-checkpoint response.

TL;DR: 2,4-Difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3- pyridinyl}benzenesulfonamide (GSK2126458, 1) has been identified as a highly potent, orally bioavailable inhibitor of PI3Kα and mTOR with in vivo activity in both pharmacodynamic and tumor growth efficacy models.

TL;DR: A 10-fold increase in affinity for IL-1 beta was achieved by combining two of the phage-selected single amino acid substitutions in CDR3-H, thereby demonstrating that a significant improvement in affinity can be achieved through CDR mutagenesis, even in a matured Ab.